Pharma Roundup: Cephalon's Strategy, GSK: "No Big M&A," and More

Recommended Sources

About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Cephalon’s winning business model — Time and time again, Cephalon buys a drug for cheap and then gives it the resources to become a success, earning big money in the process — 2009 revenue for the company should top $2 billion. Combined with “superior drug scouting” and “hyperaggressive marketing,” it’s added up to success, as analyzed in an article from Investor’s Business Daily. [Source: Yahoo Finance, via Corey Nahman]

GlaxoSmithKline uninterested in mega-mergers — “I don’t particularly believe that big M&A is going to be a great solution to anything in the next few years,” CEO Andrew Witty said. He said GSK is looking for smaller acquisitions that can integrate smoothly with existing operations. [Source: PharmaTimes]

J&J subsidiary Janssen partners with Vanderbilt University — Janssen, owned by Johnson & Johnson, will pay up to $100 million to Vanderbilt; Vanderbilt, in turn, will develop potential treatments for schizophrenia until they are ready for human trials. [Source: FierceBiotech]

“The amount of revenue generated by the average new medicine is dropping.” — This according to a report from IMS Health. [Source: Forbes, via Corey Nahman]

Tags: Strategy, Johnson & Johnson, M&A, Cephalon Inc., Vanderbilt University, Mergers & Acquisitions, Operational Accounting, Investment, Finance, John Maas

BNET User Analysis

Voice your 2cents

Web Buzz:

Big Food vs. Mother Nature

Ethicurean - 172 days 7 hours 23 minutes ago

Money can’t buy you cheap oil again: FoE Tom Laskawy has a nice overview of Big Food’s recent desperate-seeming lobbying efforts, before launching into how the one threat Big Food hasn’t proven itself very adept at handling is “the multiheaded hydra of climate change, drought, and the shrinking supplies of various natural...
Top tips to protect your deposit

Times Online - 242 days 7 hours 27 minutes ago

With renting now more popular than buying, many people are becoming tenants for the first time. If you are not careful, however, this could mean handing over a deposit and never seeing your money again. Follow our ten tips to give yourself the best chance of regaining your full deposit. 1. Be prepared Do not rush into a rental contract to secure...
Amgen Q2: Don't Call It a Comeback, Call it a Growth Story (In More Ways Than D-Mab)

BNET Pharma - 118 days 1 hour 49 minutes ago

Amgens Q408 earnings were marred by a perfect storm of safety, regulatory and reimbursement issues converging on its erythropoiesis-stimulating agent franchise, and Q109 earnings took a hit thanks to economic woes pressuring patients to forgo pricey meds like the anti-inflammatry drug Enbrel (etanercept). But with Q209, everyones...
Where Five Magazines Are Finding Revenue

Ad Age - 92 days 3 hours 27 minutes ago

NEW YORK (AdAge.com) -- It wasn't so long ago that almost every magazine chased ever larger circulation, even if it meant losing money in the process. It worked because print-ad sales paid the bills -- and then some. Now that magazines seem unlikely to recapture the print-ad revenue they enjoyed before this recession, however, their other...
Will new label help Bristol's Orencia?

Fierce Pharma - 88 days 15 hours 29 minutes ago

Could a label change help Bristol-Myers Squibb give a big boost to arthritis remedy Orencia? The company hopes so. The drug's label had specified Orencia use for patients who didn't respond to treatment with other drugs such as methotrexate. Now, the label can carry info on using the drug in patients who have had the disease for two years or...